In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1487-1494

  Hu, Zhe Yi ^a   Parker, Robert B ^a   Laizure, S Casey ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BENZBROMARONE; BUCOLOME; CIMETIDINE; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DICLOFENAC; DILTIAZEM; DRUG METABOLITE; ETRAVIRINE; FLUCONAZOLE; FLUINDOSTATIN; FLURBIPROFEN; FLUVOXAMINE; GLIMEPIRIDE; IBUPROFEN; KETOCONAZOLE; LOSARTAN; MELOXICAM; MICONAZOLE; PAROXETINE; PHENYTOIN; SERTRALINE; SULFAPHENAZOLE; SULFINPYRAZONE; TOLBUTAMIDE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; ZAFIRLUKAST;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG INTERACTION; DRUG-DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO INFORMATION GUIDED PREDICTION; IN VIVO STUDY; INTERMETHOD COMPARISON; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ISOENZYMES;

EID: 84863932116     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045799     Document Type: Article

References (37)

1. Albers LJ, Reist C, Vu RL, Fujimoto K, Ozdemir V, Helmeste D, Poland R, and Tang SW (2000) Effect of venlafaxine on imipramine metabolism. Psychiatry Res 96:235-243.
2. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, and Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291.
3. Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, and Smith RL (1991) Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 3:14-18.
4. Backman JT, Kivistö KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58.
5. Backman JT, Olkkola KT, Aranko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
6. Brown HS, Galetin A, Hallifax D, and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
7. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
8. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
9. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-1229.
10. Hisaka A, Ohno Y, Yamamoto T, and Suzuki H (2010) Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 125:230-248.
11. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
12. Jerling M, Huan BL, Leung K, Chu N, Abdallah H, and Hussein Z (2005) Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 45:422-433.
13. Kurtz DL, Bergstrom RF, Goldberg MJ, and Cerimele BJ (1997) The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 62:145-156.
14. I,u for amiodarone and its plasma metabolites. Clin Pharmacol Ther 91:709-717.
15. Neuvonen PJ, Kantola T, and Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
16. Nolan PE Jr, Marcus FI, Hoyer GL, Bliss M, and Gear K (1989) Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 46:43-50.
17. Obach RS (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81-89.
18. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
19. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
20. Ohno Y, Hisaka A, and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696.
21. Olkkola KT, Ahonen J, and Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
22. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
23. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
24. O'Reilly RA (1982) Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation 65:202-207.
25. Polasek TM, Lin FP, Miners JO, and Doogue MP (2011) Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 71:727-736.
26. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, and Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98.
27. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
28. Shardlow CE, Generaux GT, MacLauchlin CC, Pons N, Skordos KW, and Bloomer JC (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39:2076-2084.
29. Shou M (2005) Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discov Devel 8:66-77.
30. Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, and Charpiat B (2011) Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet 50:519-530.
31. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, and Goulart DA (1986) The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 39:15-24.
32. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions? Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
33. Zamuner S, Johnson BM, Pagliarusco S, Fina P, Peroni M, Fiore M, Adams LM, and Fernandes SA (2010) Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol 70:537-546.
34. Zhang X, Jones DR, and Hall SD (2009a) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37:150-160.
35. Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009b) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597.
36. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, et al. (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267.
37. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, and Wildfeuer A (1996) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel-Forschung 46:213-217.